BLU Trial

This study is currently closed to enrollment.

Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

tube of blood

AGE: 18+ years old
SEX AT BIRTH: All

TYPE: Interventional Study
HEALTHY PARTICIPANTS: No

CONDITION: Systemic Mastocytosis (SM) and Indolent
LOCATION: University Hospitals Rainbow Babies & Children’s

Study Purpose

The purpose of this study is to learn more about the safety and effectiveness of an experimental drug called avapritinib (formerly called BLU285), when given to individuals who have been diagnosed with ISM.

Study ID

NCT03580655